Skip to main content
Cancers logoLink to Cancers
. 2024 Aug 1;16(15):2744. doi: 10.3390/cancers16152744

Correction: Tasci et al. RadWise: A Rank-Based Hybrid Feature Weighting and Selection Method for Proteomic Categorization of Chemoirradiation in Patients with Glioblastoma. Cancers 2023, 15, 2672

Erdal Tasci 1, Sarisha Jagasia 1, Ying Zhuge 1, Mary Sproull 1, Theresa Cooley Zgela 1, Megan Mackey 1, Kevin Camphausen 1, Andra Valentina Krauze 1,*
PMCID: PMC11311443  PMID: 39123498

In the original publication [1], there was a mistake shown in Tables 1–8 and Figures 3–5 and 7 as published. The pre/post-categorization information of four patients in our proteomic dataset was incorrectly labeled, requiring the proteomic analysis to be repeated. We repeated our analyses depending on the newly constructed, corrected, and normalized dataset. The newly obtained results are given in the corrected Table 1, Table 2, Table 3, Table 4, Table 5, Table 6, Table 7 and Table 8 and Figure 3, Figure 4 and Figure 5 and Figure 7 below.

Table 1.

Accuracy rates: Five supervised learning models with or without feature selection. Color changes from red to green display performance results from the lowest (red) to the highest values (green).

ML-ACC Without FS LASSO FS mRMR FS
SVM 57.860 78.674 91.515
LR 67.633 85.341 92.708
KNN 62.197 53.068 88.466
RF 73.826 88.466 89.659
AdaBoost 88.409 89.072 88.447

Table 2.

Performance results (i.e., ACC%) using only LASSO-based feature selection and weighting methods. Color changes from red to green display performance results from the lowest (red) to the highest values (green). The bold value indicates the best result.

k # of Features SVM LR KNN RF AdaBoost
5 11 93.314 92.083 82.386 91.496 91.477
4 26 89.640 93.314 62.197 93.939 90.890
3 44 89.053 96.363 46.345 92.121 93.939
2 90 85.985 92.064 60.379 91.496 93.901
1 197 76.269 85.966 54.868 87.841 87.822

Table 3.

Performance results (i.e., ACC%) using only mRMR-based feature selection and weighting methods. Color changes from red to green display performance results from the lowest (red) to the highest (green) values. The bold value indicates the best result.

k # of Features SVM LR KNN RF AdaBoost
5 5 86.004 88.428 87.235 87.841 87.197
4 7 90.890 92.708 90.265 91.496 91.496
3 8 95.152 96.364 92.708 90.871 93.920
2 11 92.708 96.364 92.689 90.284 94.508
1 34 92.102 92.102 87.254 92.121 90.871

Table 4.

Mean performance results (i.e., ACC %, CV = 5) determined using both LASSO and mRMR-based feature selection with weighting methods. Color changes from red to green display performance results from the lowest (red) to the highest values (green). The bold value indicates the best result.

k # of Features SVM LR KNN RF AdaBoost
15 2 87.216 87.216 89.659 87.841 85.379
14 2 87.216 87.216 89.659 87.841 85.379
13 4 90.265 90.265 90.284 92.727 89.034
12 6 93.920 92.708 91.477 92.102 93.314
11 6 93.920 92.708 91.477 92.102 93.314
10 8 95.152 96.364 92.708 90.265 93.920
9 8 95.152 96.364 92.708 90.265 93.920
8 8 95.152 96.364 92.708 90.265 93.920
7 10 93.333 94.546 90.284 92.102 90.284
6 12 93.939 95.152 90.909 91.496 90.246
5 17 96.345 95.114 88.447 91.496 90.871
4 32 93.295 95.739 68.921 90.890 89.640
3 52 92.121 95.151 49.962 93.333 92.670
2 113 87.216 92.670 60.379 91.496 95.152
1 218 78.087 85.966 55.492 89.053 93.314

Table 5.

The standard deviation of performance results (i.e., ACC %, CV = 5) determined using both LASSO and mRMR-based feature selection with weighting methods. Color changes from red to green display performance results from the lowest (red) to the highest values (green).

k # of Features SVM LR KNN RF AdaBoost
15 2 5.175 4.408 4.072 4.232 2.191
14 2 5.175 4.408 4.072 4.232 2.191
13 4 4.423 4.821 4.425 4.924 2.384
12 6 5.060 5.269 3.509 4.088 3.515
11 6 5.060 5.269 3.509 4.088 3.515
10 8 3.636 4.454 5.269 3.496 4.272
9 8 3.636 4.454 5.269 3.496 4.272
8 8 3.636 4.454 5.269 3.496 4.272
7 10 4.848 5.555 4.425 4.088 4.425
6 12 4.285 3.636 6.357 3.995 3.526
5 17 2.966 2.444 3.476 4.827 5.400
4 32 6.177 4.105 6.384 4.259 1.442
3 52 4.535 2.424 7.329 4.020 2.469
2 113 4.807 1.557 4.954 4.430 4.924
1 218 4.720 3.133 5.559 3.031 3.515

Table 6.

Performance results without employing feature selection and feature weighting. Color changes from red to green display performance results from the lowest (red) to the highest values (green).

ML ACC% AUC F1 PRE REC SPEC
SVM 57.860 0.415 0.518 0.698 0.515 0.690
LR 67.633 0.755 0.676 0.681 0.681 0.673
KNN 62.197 0.647 0.581 0.662 0.527 0.722
RF 73.826 0.808 0.744 0.768 0.746 0.737
AdaBoost 88.409 0.951 0.886 0.882 0.893 0.873

Table 7.

Performance results employing LASSO and mRMR-based feature selection with weighting operation. Color changes from red to green display performance results from the lowest (red) to the highest values (green).

ML ACC% AUC F1 PRE REC SPEC
SVM 95.152 0.989 0.949 0.975 0.928 0.976
LR 96.364 0.987 0.964 0.963 0.965 0.965
KNN 92.708 0.965 0.930 0.929 0.932 0.923
RF 90.265 0.978 0.902 0.885 0.928 0.876
AdaBoost 93.920 0.979 0.941 0.941 0.942 0.935

The best ACC% is 96.364, which was obtained with the Logistic Regression Model, and the minimum weight is 10. Selected Number of Features: 8. Best Feature (Biomarker) Set is as follows: ‘K2C5’, ‘MIC-1’, ‘CSPG3’, ‘GFAP’, ‘Proteinase-3’, ‘STRATIFIN’, ‘Cystatin M’, and ‘Keratin-1’ [59].

Table 8.

Overview of the identified proteomic biomarkers illustrating the biological relevance to glioma.

Entrez Gene Symbol Target Full Name Biological Relevance to Glioma
K2C5 Keratin, type II cytoskeletal 5 Yes, evolving biomarker/target [61]
Keratin-1 Keratin, type II cytoskeletal 1 Yes, evolving biomarker/target [61]
STRATIFIN
(SFN)
14-3-3 protein sigma Yes, tumor suppressor gene expression pattern correlates with glioma grade and prognosis [62]
MIC-1 (GDF15) Growth/differentiation factor 15 Yes, biomarker, novel immune checkpoint [63]
GFAP Glial fibrillary acidic protein Yes, evolving biomarker/target [64]
CSPG3 (NCAN) Neurocan core protein Yes, glycoproteomic profiles of GBM subtypes, differential expression versus control tissue [65]
Cystatin M (CST6) Cystatin M Yes, cell type-specific expression in normal brain and epigenetic silencing in glioma [66]
Proteinase-3
(PRTN3)
Proteinase-3 Yes, evolving role, may relate to pyroptosis, oxidative stress and immune response [59]

Figure 3.

Figure 3

The visualization of the effects of the feature selection procedures with accuracy (ACC%) determined by a supervised learning method in conjunction with the feature selection approach (mRMR FS (yellow), LASSO FS (blue), and no FS (green)).

Figure 4.

Figure 4

The effects of the number of features related to the minimum weight value using LASSO and mRMR-based feature selection with weighting methods.

Figure 5.

Figure 5

Mean accuracy rate (ACC) vs. minimum weight stratified by model employed in analysis.

Figure 7.

Figure 7

Ingenuity pathway analysis (IPA) carried out on April 5, 2023, illustrating linkage of the identified protein features to the top 2 upstream mediators (Supplementary Data Table S2). (A) Epidermal growth factor (EGF) (p-value of overlap 2.53 × 10−7). (B) Catenin beta 1 (CTNNB1) (p-value of overlap 2.41 × 10−6). (C) IPA-generated merged network for the 8 ML-identified proteins using the disease classification brain cancer.

References

  • 59.

    Zeng, S.; Li, W.; Ouyang, H.; Xie, Y.; Feng, X.; Huang, L. A Novel Prognostic Pyroptosis-Related Gene Signature Correlates to Oxidative Stress and Immune-Related Features in Gliomas. Oxid. Med. Cell. Longev. 2023, 2023, 4256116. https://doi.org/10.1155/2023/4256116.

The repeat analysis has resulted in superior results as compared to the previous analysis with the best ACC% now 96.364, which was obtained with the Logistic Regression Model, and the minimum weight of 10. The selected number of features is now 8. Best Feature (Biomarker) Set is as follows: ‘K2C5’, ‘MIC-1’, ‘CSPG3’, ‘GFAP’, ‘STRATIFIN’, ‘Cystatin M’, ‘Keratin-1’ and ‘Proteinase-3’. All places in the manuscript text where the new results have resulted in a numerical change e.g., ACC, AUC, have been corrected to reflect the new findings in the updated tables. With this correction, the order of some references has been adjusted accordingly. The authors state that the scientific conclusions are unaffected. This correction was approved by the Academic Editor. The original publication has also been updated.

Footnotes

Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.

Reference

  • 1.Tasci E., Jagasia S., Zhuge Y., Sproull M., Cooley Zgela T., Mackey M., Camphausen K., Krauze A.V. RadWise: A Rank-Based Hybrid Feature Weighting and Selection Method for Proteomic Categorization of Chemoirradiation in Patients with Glioblastoma. Cancers. 2023;15:2672. doi: 10.3390/cancers15102672. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Cancers are provided here courtesy of Multidisciplinary Digital Publishing Institute (MDPI)

RESOURCES